• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor
    Hero Background

    US Depression Screening Mental Health Market

    ID: MRFR/Pharma/11780-HCR
    100 Pages
    Garvit Vyas
    October 2025

    US Depression Screening Mental Health Market Research Report: By Indication (Major Depressive Disorder, Anxiety Distress, Bipolar Disorder, Psychotic Disorders, Others), By Diagnosis (Psychological Tests, Blood Tests, Pharmacogenomic Testing, Others) and By End User (Hospitals and Clinics, Home-based, Research and Academic Institutes) - Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    US Depression Screening Mental Health Market Infographic
    Purchase Options

    US Depression Screening Mental Health Market Summary

    As per MRFR analysis, the US depression screening market size was estimated at 178.98 USD Million in 2024. The US depression screening-mental-health market is projected to grow from 189.48 USD Million in 2025 to 335.27 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 5.87% during the forecast period 2025 - 2035.

    Key Market Trends & Highlights

    The US The depression screening market is experiencing robust growth, driven by technological advancements and increased awareness.

    • Technological integration in screening tools is enhancing the accuracy and efficiency of depression assessments.
    • Increased awareness and advocacy for mental health are driving demand for screening services across various demographics.
    • The focus on preventive care is leading to a rise in early detection initiatives, particularly among the largest segment of adults aged 18-64.
    • Rising prevalence of depression and policy support for mental health initiatives are key drivers propelling market expansion.

    Market Size & Forecast

    2024 Market Size 178.98 (USD Million)
    2035 Market Size 335.27 (USD Million)

    Major Players

    UnitedHealth Group (US), Anthem (US), Cigna (US), Kaiser Permanente (US), CVS Health (US), Teladoc Health (US), Mental Health America (US), Lemonaid Health (US)

    US Depression Screening Mental Health Market Trends

    The depression screening market is currently experiencing notable shifts driven by various factors. Increased awareness surrounding mental health issues has led to a growing demand for effective screening tools. This heightened focus on mental well-being is reflected in the rising number of individuals seeking professional help. Furthermore, the integration of technology into mental health services appears to enhance accessibility and efficiency in screening processes. Telehealth platforms and mobile applications are becoming more prevalent, allowing for remote assessments and follow-ups, which may contribute to improved patient outcomes. In addition, The emphasis on preventive care is reshaping the landscape of the depression screening market. Healthcare providers are increasingly recognizing the importance of early detection and intervention. This proactive approach not only aids in reducing the severity of mental health conditions but also alleviates the overall burden on healthcare systems. As a result, there is a growing investment in research and development of innovative screening methods, which could potentially lead to more accurate and user-friendly tools. Overall, the current trends suggest a dynamic evolution in the market, driven by technological advancements and a cultural shift towards prioritizing mental health.

    Technological Integration

    The incorporation of technology into the depression screening-mental-health market is transforming traditional practices. Digital platforms and mobile applications facilitate remote assessments, making it easier for individuals to access screening tools. This trend not only enhances convenience but also encourages more people to seek help, potentially leading to earlier interventions.

    Increased Awareness and Advocacy

    There is a growing societal awareness regarding mental health issues, which is influencing the depression screening-mental-health market. Advocacy efforts are promoting the importance of mental well-being, leading to more individuals recognizing the need for screening. This shift in perception is likely to drive demand for effective screening solutions.

    Focus on Preventive Care

    The emphasis on preventive care is reshaping the approach to mental health. Healthcare providers are increasingly prioritizing early detection of depression, which may reduce the long-term impact of mental health conditions. This trend is fostering investment in innovative screening methods that aim to improve accuracy and accessibility.

    US Depression Screening Mental Health Market Drivers

    Policy and Regulatory Support

    Government policies and regulations play a pivotal role in shaping the depression screening-mental-health market. Recent legislative efforts have focused on enhancing mental health services, including the integration of depression screening into primary care settings. The Mental Health Parity and Addiction Equity Act mandates that mental health services be covered by insurance plans, which may lead to increased access to screening. Furthermore, the Centers for Medicare & Medicaid Services have introduced reimbursement codes for depression screening, incentivizing healthcare providers to adopt these practices. This regulatory support is expected to drive market growth, as more individuals gain access to necessary screening services, ultimately improving mental health outcomes across the population.

    Rising Prevalence of Depression

    The increasing prevalence of depression in the US is a critical driver for the depression screening market. Recent studies indicate that approximately 8.4% of adults experience major depressive episodes annually. This rising trend necessitates effective screening methods to identify individuals in need of mental health support. As awareness grows, healthcare providers are more likely to implement standardized screening protocols, thereby expanding the market. The National Institute of Mental Health reports that untreated depression can lead to significant economic burdens, estimated at over $210 billion annually in lost productivity and healthcare costs. Consequently, the demand for effective screening tools and interventions is likely to increase, propelling growth in the depression screening-mental-health market.

    Increased Collaboration Among Stakeholders

    Collaboration among various stakeholders, including healthcare providers, insurers, and community organizations, is driving the depression screening-mental-health market. This collaborative approach aims to create comprehensive mental health care systems that prioritize early detection and intervention. Partnerships between public health agencies and private organizations are facilitating the development of community-based screening programs, which are essential for reaching underserved populations. The Substance Abuse and Mental Health Services Administration emphasizes the importance of such collaborations in improving access to mental health services. As these partnerships expand, the market is likely to benefit from increased awareness, resources, and support for depression screening initiatives.

    Growing Focus on Mental Health in Education

    The emphasis on mental health within educational institutions is emerging as a significant driver for the depression screening-mental-health market. Schools and universities are increasingly recognizing the importance of mental health support for students. Initiatives aimed at implementing mental health screenings in educational settings are becoming more common, with many institutions adopting programs to identify and assist students experiencing depression. The National Alliance on Mental Illness reports that 1 in 5 youth experience a mental health condition, highlighting the need for early intervention. By integrating screening into educational frameworks, the market is likely to see growth as more young individuals receive the necessary support and resources to address their mental health needs.

    Technological Advancements in Screening Tools

    Technological advancements are transforming the landscape of the depression screening-mental-health market. Innovations such as digital screening tools, mobile applications, and telehealth services are making it easier for individuals to access mental health assessments. For instance, the use of artificial intelligence in developing predictive algorithms for depression screening is gaining traction. These tools can analyze patient data more efficiently, leading to quicker and more accurate diagnoses. The integration of technology not only enhances the screening process but also encourages individuals to seek help, thereby expanding the market. As the demand for convenient and accessible mental health solutions grows, the adoption of these advanced screening tools is likely to increase.

    Market Segment Insights

    By Indication: Major Depressive Disorder (Largest) vs. Anxiety Distress (Fastest-Growing)

    In the US depression screening-mental-health market, Major Depressive Disorder holds the largest share among different indication values, indicating a significant prevalence and demand for targeted screening methods. Anxiety Distress also demonstrates notable traction, suggesting that while Major Depressive Disorder remains central, growing awareness and screening efforts for anxiety-related conditions are gaining ground. Growth trends within this segment highlight a rise in mental health awareness, increased stigma reduction, and greater accessibility to mental health resources. Major Depressive Disorder continues to dominate due to its widespread recognition, but Anxiety Distress is rapidly emerging, encouraged by initiatives aimed at addressing anxiety as a critical mental health concern. This shift is driving innovation in screening tools and treatment options tailored for these conditions.

    Major Depressive Disorder (Dominant) vs. Anxiety Distress (Emerging)

    Major Depressive Disorder, as the dominant indication within the US depression screening-mental-health market, is characterized by its profound impact on individuals and the healthcare system. It is often prioritized in screenings due to its high prevalence and serious consequences if left untreated. Meanwhile, Anxiety Distress is gaining prominence as an emerging indication, driven by increased recognition of its correlation with Major Depressive Disorder. The rise in dual diagnoses presents both challenges and opportunities for mental health providers. Innovations in screening techniques, combined with the growing focus on holistic mental health, are likely to enhance service delivery and improve outcomes across these indications.

    By Diagnosis: Psychological Tests (Largest) vs. Blood Tests (Fastest-Growing)

    In the US depression screening-mental-health market, Psychological Tests dominate with a significant share, reflecting their established role in diagnosing mental health disorders. Blood Tests have been gaining traction, appealing to those looking for biological markers to aid in diagnoses and treatment plans, contributing to a competitive landscape amid rising awareness of mental health issues. Growth trends in this segment are fueled by increasing investments in mental health technologies and a push for personalized approaches to treatment. The adoption of Blood Tests, noted for their advancements in pharmacogenomics, is particularly significant, enabling tailored treatment plans based on individual biological responses. This reflects a broader shift towards integrated care methods, enhancing diagnostic processes for mental health practitioners.

    Psychological Tests: Dominant vs. Blood Tests: Emerging

    Psychological Tests represent the dominant segment in the US depression screening-mental-health market, primarily due to their long-standing application in assessing mood disorders and providing structured evaluations. These tests typically encompass a range of standardized questionnaires and assessments, aiding clinicians in diagnosing complex mental health issues. Conversely, Blood Tests are emerging as a viable alternative, appealing to a demographic seeking more scientifically grounded methods of diagnosis. Blood Tests leverage advancements in pharmacogenomic research to predict patient responses to certain antidepressants, thereby fostering a personalized treatment approach. This adaptability is critical as patients and healthcare providers increasingly seek testing methods that offer clear insights into treatment efficacy and potential side effects.

    By End User: Hospitals and Clinics (Largest) vs. Home-based (Fastest-Growing)

    In the US depression screening-mental-health market, hospitals and clinics hold the largest share, demonstrating a robust infrastructure for mental health services. These institutions are often the first point of contact for individuals seeking help, equipped with trained professionals and resources that cater to various mental health needs. Home-based services, on the other hand, are rapidly gaining traction due to the increasing preference for convenience and privacy. Patients appreciate the flexibility that home-based screening provides, leading to a significant shift in patient engagement strategies. The growth trends in the end user segment are heavily influenced by technological advancements and a greater public awareness of mental health issues. Hospitals and clinics are adapting to integrate digital screening tools, enhancing accessibility for patients. Meanwhile, the home-based services are being driven by teletherapy and digitalization, which empower patients to manage their mental health from the comfort of their homes. Research and academic institutes contribute through studies that advance screening techniques, further propelling innovation in the sector.

    Hospitals and Clinics (Dominant) vs. Home-based (Emerging)

    Hospitals and clinics serve as the dominant force in the US depression screening-mental-health market, leveraging established protocols and a wide array of medical professionals. Their integrated approach, combining psychological evaluation with medical assessment, ensures comprehensive care for those suffering from mental health issues. As they continue to invest in advanced technologies and training, hospitals and clinics are positioned to maintain their leadership role. Conversely, home-based services are emerging, driven by the growing desire for personalized care and the sense of safety provided by home environments. This segment's flexibility, combined with the rise in telehealth applications, enables it to cater effectively to a broader audience, including those hesitant to seek traditional in-clinic services.

    Get more detailed insights about US Depression Screening Mental Health Market

    Key Players and Competitive Insights

    The depression screening market in the US is characterized by a dynamic competitive landscape, driven by increasing awareness of mental health issues and the growing demand for accessible screening solutions. Major players such as UnitedHealth Group (US), Anthem (US), and Teladoc Health (US) are strategically positioned to leverage digital transformation and innovative service delivery models. UnitedHealth Group (US) focuses on integrating behavioral health services into its broader health plans, enhancing patient access and care coordination. Meanwhile, Anthem (US) emphasizes partnerships with technology firms to expand its telehealth offerings, thereby improving patient engagement and outcomes. Teladoc Health (US) continues to innovate through its virtual care platform, which integrates mental health services with primary care, reflecting a holistic approach to health management. Collectively, these strategies contribute to a competitive environment that prioritizes accessibility, integration, and patient-centric care.

    The market structure appears moderately fragmented, with a mix of large insurers and specialized mental health service providers. Key players are employing various business tactics, such as optimizing their supply chains and localizing service delivery to enhance responsiveness to patient needs. This fragmentation allows for diverse service offerings, yet the influence of major players remains significant, as they set standards for quality and accessibility in mental health care.

    In October 2025, UnitedHealth Group (US) announced a partnership with a leading telehealth platform to enhance its mental health screening capabilities. This strategic move is likely to bolster its service offerings, allowing for more comprehensive mental health assessments and timely interventions. By integrating advanced telehealth solutions, UnitedHealth Group (US) aims to improve patient outcomes and streamline care delivery, positioning itself as a leader in the mental health space.

    In September 2025, Anthem (US) launched a new initiative aimed at expanding access to mental health services through community-based programs. This initiative is significant as it reflects a commitment to addressing mental health disparities, particularly in underserved populations. By focusing on community engagement and local partnerships, Anthem (US) is likely to enhance its brand reputation and foster loyalty among its members, while also contributing to broader public health goals.

    In August 2025, Teladoc Health (US) introduced an AI-driven mental health assessment tool designed to provide personalized care recommendations. This innovation underscores the growing trend of integrating artificial intelligence into mental health services, potentially improving the accuracy and efficiency of screenings. As AI continues to evolve, Teladoc Health (US) is well-positioned to capitalize on this technology, enhancing its competitive edge in the market.

    As of November 2025, current trends in the depression screening-mental-health market include a pronounced shift towards digitalization and the integration of AI technologies. Strategic alliances among key players are shaping the landscape, fostering innovation and enhancing service delivery. The competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, quality of care, and supply chain reliability. This shift suggests that companies that prioritize innovation and patient-centric solutions will be better positioned to thrive in the increasingly complex mental health market.

    Key Companies in the US Depression Screening Mental Health Market market include

    Industry Developments

    The US Depression Screening Mental Health Market has recently seen notable developments. American Well continues expanding its virtual care services, reflecting a growing trend towards telehealth solutions. In October 2023, Talkspace announced enhancements to its platform, focusing on personalized therapy options, an area of rising demand. MDLIVE reported an increase in user engagement, underlining the effectiveness of remote mental health services.

    In terms of acquisitions, in August 2023, BetterHelp acquired the digital therapy platform offered by a leading competitor, enhancing its service offerings and market reach. Pear Therapeutics launched new initiatives aimed at integrating digital therapeutics with traditional therapy for enhanced patient outcomes. The overall market is experiencing growth, with estimates from governmental health agencies suggesting a significant uptick in demand for mental health services, driven by increased awareness and the ongoing impact of the COVID-19 pandemic.

    Companies like Lyra Health, Calm, and Spring Health remain prominent as they innovate to meet the needs of users seeking mental health support. The combination of innovative technology, strategic mergers, and heightened demand is shaping the landscape of the US Depression Screening Mental Health Market.

    Future Outlook

    US Depression Screening Mental Health Market Future Outlook

    The depression screening-mental-health market is projected to grow at a 5.87% CAGR from 2024 to 2035, driven by increasing awareness and technological advancements.

    New opportunities lie in:

    • Integration of AI-driven diagnostic tools for personalized treatment plans.
    • Expansion of telehealth services to reach underserved populations.
    • Development of subscription-based mental health support platforms.

    By 2035, the market is expected to be robust, reflecting significant advancements and increased accessibility.

    Market Segmentation

    US Depression Screening Mental Health Market End User Outlook

    • Hospitals and Clinics
    • Home-based
    • Research and Academic Institutes

    US Depression Screening Mental Health Market Diagnosis Outlook

    • Psychological Tests
    • Blood Tests
    • Pharmacogenomic Testing
    • Others

    US Depression Screening Mental Health Market Indication Outlook

    • Major Depressive Disorder
    • Anxiety Distress
    • Bipolar Disorder
    • Psychotic Disorders
    • Others

    Report Scope

    MARKET SIZE 2024 178.98(USD Million)
    MARKET SIZE 2025 189.48(USD Million)
    MARKET SIZE 2035 335.27(USD Million)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 5.87% (2024 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    Market Forecast Period 2025 - 2035
    Historical Data 2019 - 2024
    Market Forecast Units USD Million
    Key Companies Profiled UnitedHealth Group (US), Anthem (US), Cigna (US), Kaiser Permanente (US), CVS Health (US), Teladoc Health (US), Mental Health America (US), Lemonaid Health (US)
    Segments Covered Indication, Diagnosis, End User
    Key Market Opportunities Integration of digital health solutions enhances accessibility and efficiency in the depression screening-mental-health market.
    Key Market Dynamics Rising demand for digital screening tools drives innovation and competition in the depression screening-mental-health market.
    Countries Covered US

    Leave a Comment

    FAQs

    What is the expected market size of the US Depression Screening Mental Health Market in 2024?

    The US Depression Screening Mental Health Market is expected to be valued at 178.85 million USD in 2024.

    What will be the projected market size of the US Depression Screening Mental Health Market by 2035?

    By 2035, the US Depression Screening Mental Health Market is projected to reach 412.0 million USD.

    What is the expected CAGR for the US Depression Screening Mental Health Market from 2025 to 2035?

    The expected compound annual growth rate (CAGR) for the US Depression Screening Mental Health Market is 7.881% from 2025 to 2035.

    Which indications dominate the US Depression Screening Mental Health Market?

    Major Depressive Disorder, Anxiety Distress, Bipolar Disorder, and Psychotic Disorders are key indications in this market.

    How much is the market for Major Depressive Disorder expected to be worth in 2024?

    The market for Major Depressive Disorder is expected to be valued at 60.0 million USD in 2024.

    What is the projected market value for Anxiety Distress by 2035?

    The projected market value for Anxiety Distress is estimated to be 100.0 million USD by 2035.

    Who are the key players in the US Depression Screening Mental Health Market?

    Major players include American Well, Talkspace, MDLIVE, and BetterHelp among others.

    What is the market value for Bipolar Disorder in 2024?

    The market for Bipolar Disorder is expected to be valued at 30.0 million USD in 2024.

    How is the US Depression Screening Mental Health Market influenced by emerging trends?

    The market is influenced by trends toward increased telehealth adoption and personalized mental health solutions.

    How much is the market for Psychotic Disorders expected to grow by 2035?

    The market for Psychotic Disorders is projected to grow to 55.0 million USD by 2035.

    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    Case Study
    Chemicals and Materials

    Compare Licence

    ×
    Features License Type
    Single User Multiuser License Enterprise User
    Price $4,950 $5,950 $7,250
    Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
    Free Customization
    Direct Access to Analyst
    Deliverable Format
    Platform Access
    Discount on Next Purchase 10% 15% 15%
    Printable Versions